INSERM U633, Laboratory of Surgical Research, Paris, France.
Cell Transplant. 2012;21(4):679-91. doi: 10.3727/096368911X612440. Epub 2011 Nov 11.
Therapeutic intracavitary stem cell infusion currently suffers from poor myocardial homing. We examined whether cardiac cell retention could be enhanced by magnetic targeting of endothelial progenitor cells (EPCs) loaded with iron oxide nanoparticles. EPCs were magnetically labeled with citrate-coated iron oxide nanoparticles. Cell proliferation, migration, and CXCR4 chemokine receptor expression were assessed in different labeling conditions and no adverse effects of the magnetic label were observed. The magnetophoretic mobility of labeled EPCs was determined in vitro, with the same magnet as that subsequently used in vivo. Coronary artery occlusion was induced for 30 min in 36 rats (31 survivors), followed by 20 min of reperfusion. The rats were randomized to receive, during brief aortic cross-clamping, direct intraventricular injection of culture medium (n = 7) or magnetically labeled EPCs (n = 24), with (n = 14) or without (n = 10) subcutaneous insertion of a magnet over the chest cavity (n = 14). The hearts were explanted 24 h later and engrafted cells were visualized by magnetic resonance imaging (MRI) of the heart at 1.5 T. Their abundance in the myocardium was also analyzed semiquantitatively by immunofluorescence, and quantitatively by real-time polymerase chain reaction (RT-PCR).Although differences in cell retention between groups failed to be statistically significant using RT-PCR quantification, due to the variability of the animal model, immunostaining showed that the average number of engrafted EPCs was significantly ten times higher with than without magnetic targeting. There was thus a consistent trend favoring the magnet-treated hearts, thereby suggesting magnetic targeting as a potentially new mean of enhancing myocardial homing of intravascularly delivered stem cells. Magnetic targeting has the potential to enhance myocardial retention of intravascularly delivered endothelial progenitor cells.
治疗性的腔内干细胞输注目前存在归巢心肌效率差的问题。我们研究了载氧化铁纳米颗粒的内皮祖细胞(EPC)经磁靶向作用后,其心脏细胞的保留能力是否可以增强。EPC 经柠檬酸铁纳米颗粒磁标记后,我们检测了不同标记条件下细胞的增殖、迁移和趋化因子受体 CXCR4 的表达情况,且未观察到磁标记的不良反应。通过体外测定标记的 EPC 的电泳迁移率,使用与体内后续使用的相同磁铁。在 36 只大鼠(31 只存活)中诱导 30 分钟的冠状动脉闭塞,随后进行 20 分钟的再灌注。大鼠随机接受短暂主动脉夹闭期间直接向心室腔内注射培养基(n = 7)或磁标记的 EPC(n = 24),其中(n = 14)或不(n = 10)在胸部皮下插入磁铁(n = 14)。24 小时后取出心脏,通过 1.5 T 的心脏磁共振成像(MRI)观察移植细胞。通过免疫荧光半定量分析和实时聚合酶链反应(RT-PCR)定量分析心肌中细胞的丰度。尽管由于动物模型的变异性,使用 RT-PCR 定量分析时,各组间细胞保留的差异没有统计学意义,但免疫染色显示,与没有磁靶向作用相比,磁靶向作用后移植的 EPC 数量平均增加了 10 倍。因此,存在有利于磁处理心脏的一致趋势,从而表明磁靶向作用可能是增强血管内递送的干细胞归巢的一种新方法。磁靶向作用有可能增强血管内递送的内皮祖细胞在心肌中的保留能力。
Cell Transplant. 2011-11-11
Zhonghua Yi Xue Za Zhi. 2007-3-13
Zhonghua Gan Zang Bing Za Zhi. 2009-1
Tissue Eng Part B Rev. 2025-6
Pharmaceutics. 2022-5-26
Biomed Eng Lett. 2020-3-13